Exodus Point Capital Management, LP Collegium Pharmaceutical, Inc Transaction History

Exodus Point Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$31.23 - $40.91 $2.77 Million - $3.62 Million	88,603 New	88,603 $3.44 Million
Q2 2023 Aug 10, 2023	SELL	$21.06 - $24.0 $645,847 - $736,008	-30,667 Reduced 68.16%	14,324 $308,000
Q1 2023 May 11, 2023	BUY	$23.0 - $29.88 $1.03 Million - $1.34 Million	44,991 New	44,991 $1.08 Million
Q3 2022 Nov 10, 2022	SELL	$15.46 - $20.1 $154,785 - $201,241	-10,012 Closed	0 $0
Q2 2022 Aug 19, 2022	SELL	$14.22 - $20.88 $12,627 - $18,541	-888 Reduced 8.15%	10,012 $177,000
Q1 2022 May 13, 2022	SELL	$17.2 - $22.5 $304,801 - $398,722	-17,721 Reduced 61.92%	10,900 $222,000
Q4 2021 Feb 11, 2022	BUY	$17.5 - $21.35 $500,867 - $611,058	28,621 New	28,621 $535,000
Q1 2021 May 17, 2021	SELL	$19.25 - $26.1 $200,508 - $271,857	-10,416 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$17.83 - $22.29 $311,828 - $389,829	-17,489 Reduced 62.67%	10,416 $209,000
Q3 2020 Nov 16, 2020	BUY	$15.78 - $20.82 $440,340 - $580,982	27,905 New	27,905 $581,000

236

39.4M

84.2K

18.6K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.36B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.